Home / Themes / HaveNots Shorts '25: Premium Subscriptions
HaveNots Shorts '25: Premium Subscriptions
Last updated
Theme thesis · 3/5 sections · Tickers 3 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsThis short basket targets non-essential, premium-priced digital and lifestyle subscriptions—especially those dependent on affluent or aspirational users with di
Thesis
This short basket targets non-essential, premium-priced digital and lifestyle subscriptions—especially those dependent on affluent or aspirational users with discretionary income. These companies rely on habit formation and perceived personal value to justify recurring spend. In a tightening economy where the top decile pulls back, middle-class wallets are maxed, and MAUs plateau, the thesis is that many of these offerings become low-priority cancel targets as consumers rebalance their budgets and churn rises.
Bull case
Consumer Subscription Rationalization: Premium fitness (PTON, LTH, XPOF) and self-improvement services (DUOL, HIMS, YOU) are seeing rising churn as users trim monthly spend
Adoption Curves Have Flattened: Penetration for SPOT and NYT subscriptions is plateauing in mature markets, with limited pricing power left.
Wealth Effect Pressure Hits Digital Discretionary: Companies relying on top 20% income consumers for upsells or retention are facing meaningful downgrades in paid MAU growth.
Bear case
High Retention Despite Downturn: Consumers maintain small indulgences—premium digital subs prove stickier than expected due to perceived utility or low switching costs.
Global Upside Compensates: U.S. fatigue offset by international user growth or bundling into utility-like ecosystems.
Ad Models Drive Margins: Freemium services or ad-supported versions (e.g. SPOT, NYT) see expanding monetization even as paid subs flatten.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Paid MAU Growth vs Free Tier Growth | Monthly | Captures whether platforms like DUOL, SPOT, and NYT are losing upgrade momentum. | Google_Sheets |
| Monthly Churn Rate by Income Cohort | Monthly | Tracks how quickly users are canceling non-essential services across income tiers. | Google_Sheets |
| Avg. Revenue per Sub in Lifestyle & Wellness | Monthly | Indicates pressure on fitness/wellness subs like PTON, LTH, XPOF as consumers downshift. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| DUOL_a28ef623 | over the course of this year | 2026-03-01 | 2026-12-31 | Rollout and A/B testing of AI features, specifically Video Call, into Super Duolingo, potentially with metered access. | This strategic shift aims to broaden access to advanced AI features, potentially increasing Super Duolingo subscriptions and retention. However, it carries the risk of cannibalizing higher-priced Max subscriptions, impacting overall bookings and average revenue per user (ARPU). | Ticker | 2026-02-26 | earnings_transcript | DUOL (ticker) |
| DUOL_e7ac9989 | this year | 2026-01-01 | 2026-12-31 | Development and launch of Duolingo Math with the goal of becoming the 'best tutor app for math'. | Successful expansion into new subjects like Math could significantly broaden Duolingo's total addressable market and user base, providing new avenues for DAU growth and long-term monetization, particularly given the high propensity to pay for math tutoring. | Ticker | 2026-02-26 | earnings_transcript | DUOL (ticker) |
| DUOL_f9144331 | for the next year, we're using this year | 2026-01-01 | 2026-12-31 | Evolution of Duolingo's monetization strategy to focus on value-added features and in-app purchases (e.g., avatar customizations, direct ad sales) rather than increasing friction for free users. | This shift is critical for achieving higher subscriber penetration (beyond 10% of monthly active users) while maintaining user growth. Success could lead to sustainable ARPU expansion and improved margins; failure could impact bookings and profitability. | Ticker | 2026-02-26 | earnings_transcript | DUOL (ticker) |
| DUOL_c07902da | in the coming year | 2026-02-26 | 2027-02-26 | Execution of the Board-authorized share buyback program of up to $400 million. | This represents capital allocation discipline and could provide support for the stock price, signaling management's confidence in the company's long-term value and financial strength. | Ticker | 2026-02-26 | earnings_transcript | DUOL (ticker) |
| HIMS_b020aa58 | next few years | 2026-02-23 | 2028-02-23 | Ongoing regulatory and legal scrutiny of compounded GLP-1s (FDA/DOJ engagement and potential restrictions or changes to compounding policy, including removal from shortage lists or bans on certain compounded semaglutide products). | A regulatory restriction or ban on compounded GLP-1s would remove a high-ticket, fast-growing revenue stream and could materially compress revenue and adjusted EBITDA; conversely, a favorable regulatory outcome or secured branded supply partnerships would de-risk weight-loss revenue and support guidance — the outcome affects demand, pricing, and supply strategy. | Theme | 2026-02-23 | earnings_transcript | HIMS (ticker) |
| HIMS_d445390e | throughout 2026 | 2026-01-01 | 2026-12-31 | Scaling of newer offerings (labs, low testosterone support, menopausal support) with management's view that each can 'eclipse $100 million in annual revenue' and will incrementally scale over the year. | If these specialties reach $100M run-rates they would materially diversify revenue away from GLP-1 dependence, improve retention and margins long-term; failure to scale as expected would leave the company more exposed to weight-loss/regulatory risk and pressure on growth assumptions. | Ticker | 2026-02-23 | earnings_transcript | HIMS (ticker) |
| HIMS_7a775872 | in 2026 | 2026-01-01 | 2026-12-31 | Integration and scaling of YourBio's microneedle at‑home blood-sampling technology into Hims & Hers' Labs offering (post-close integration to enable at‑home diagnostics). | Successful integration could accelerate Labs adoption, increase addressable market and data-driven personalization (raising LTV and cross-sell), while delays or poor execution would slow diagnostic-led growth and reduce anticipated unit-economics improvements. | Ticker | 2026-02-23 | earnings_transcript | HIMS (ticker) |
| HIMS_1e455609 | second half of this year | 2026-07-01 | 2026-12-31 | Signed acquisition of Eucalyptus — closing of the Eucalyptus transaction. | Closing materially expands Hims & Hers' international footprint (UK/Europe, Australia, Japan), requires upfront ~ $240M cash at close and up to $1.15B total consideration, and could materially change 2026 revenue mix, cash use, and near-term adjusted EBITDA given integration costs and expected revenue contributions. | Ticker | 2026-02-23 | earnings_transcript | HIMS (ticker) |
| HIMS_27d621bf | second half of this year | 2026-07-01 | 2026-12-31 | Management expectation that Eucalyptus will contribute at least $200 million of incremental revenue in H2 2026 upon closing. | If realized, this would meaningfully boost 2H26 and full-year international revenue, alter guidance realization and investor perception; failure to realize these contributions (due to delayed close or weaker performance) would weaken FY26 revenue and international growth assumptions. | Ticker | 2026-02-23 | earnings_transcript | HIMS (ticker) |
| DUOL_b8221c4f | late in the year (2026) for modest returns, more and more as we move into '27 and '28 for significant acceleration | 2026-10-01 | 2027-12-31 | Reacceleration of Daily Active User (DAU) growth beyond the 20% year-over-year guided for 2026, driven by product improvements in language teaching, free user experience, and new subjects. | Successful reacceleration is crucial for achieving the medium-term goal of 100 million DAUs by 2028, leading to significantly higher bookings and profit. Failure to reaccelerate could negatively impact long-term valuation and investor sentiment. | Ticker | 2026-02-26 | earnings_transcript | DUOL (ticker) |
| HIMS_8ce0db05 | within 12 to 18 months | 2027-02-23 | 2027-08-23 | Management target for the collective international business (inclusive of Eucalyptus) to reach break-even on an adjusted EBITDA basis within 12–18 months. | Achievement would validate international scaling playbook, reduce consolidated margin drag and accelerate path to 2030 EBITDA targets; failure to reach break-even would prolong international margin pressure and may require additional investment or slower expansion. | Ticker | 2026-02-23 | earnings_transcript | HIMS (ticker) |